Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors

NCT00619424 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00619424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00619424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
November 15, 2007
Completion date
September 4, 2009
Enrollment
58 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell